NCT02155465View on ClinicalTrials.gov

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Lung Cancer
Interventions
DRUG

Ruxolitinib

"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"

DRUG

Erlotinib

Erlotinib 150mg PO QD

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow

10604

Memorial Sloan Kettering West Harrison, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER